NCT01339897 - A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Healthy

Interventions

DRUG

5 mg/N6022

Intravenous formulation, given at doses of 5 mg once each day over 7 days.

DRUG

Placebo

Same administration procedures as active

DRUG

10mg/N6022

Intravenous formulation given at doses of 10 mg once each day over 7 days.

DRUG

20mg/N6022

Intravenous formulation given at doses of 20 mg once each day over 7 days.

Trial Locations (1)

Parexel International, Baltimore